Trypanosomatids of the order Kinetoplastida are major contributors to global disease and morbidity, and understanding their basic biology coupled with the development of new drug targets represents a critical need. Additionally, trypanosomes are among the more accessible divergent eukaryote experimental systems. The genome of Trypanosoma brucei contains 8,131 predicted open reading frames (ORFs), of which over half have no known homologues beyond the Kinetoplastida and a substantial number of others are poorly defined by in silico analysis. Thus, a major challenge following completion of the T. brucei genome sequence is to obtain functional data for all trypanosome ORFs. As T. brucei is more experimentally tractable than the related Trypanosoma cruzi and Leishmania spp. and shares >75% of their genes, functional analysis of T. brucei has the potential to inform a range of parasite biology. Here, we report methods for systematic mRNA ablation by RNA interference (RNAi) and for phenotypic analysis, together with online data dissemination. This represents the first systematic analysis of gene function in a parasitic organism. In total, 210 genes have been targeted in the bloodstream form parasite, representing an essentially complete phenotypic catalogue of chromosome I together with a validation set. Over 30% of the chromosome I genes generated a phenotype when targeted by RNAi; most commonly, this affected cell growth, viability, and/or cell cycle progression. RNAi against approximately 12% of ORFs was lethal, and an additional 11% had growth defects but retained short-term viability in culture. Although we found no evidence for clustering or a bias towards widely evolutionarily conserved genes within the essential ORF cohort, the putative chromosome I centromere is adjacent to a domain containing genes with no associated phenotype. Involvement of such a large proportion of genes in robust growth in vitro indicates that a high proportion of the expressed trypanosome genome is required for efficient propagation; many of these gene products represent potential drug targets.Protozoan parasites are responsible for a significant proportion of global morbidity, mortality, and economic hardship, and in most countries current control and treatment regimes are either failing or under serious threat (6). African trypanosomiasis, caused by Trypanosoma brucei spp., is responsible for tens to hundreds of thousands of human infections annually in areas of sub-Saharan Africa where the infection is endemic and is compounded by the impact of the disease on animal welfare and productivity. Without treatment trypanosomiasis is invariably fatal, and the need for new treatments is urgent. Mechanisms for combating pathogenic protozoa rely on development and exploitation of new drug targets and/or vaccine candidates as well as efforts at vector control, all of which require detailed understanding of the biology of the pathogen and its relationship with the host and vector. The presence of efficient antigenic variation in T. brucei make...